Almost all of the factors which are known to be associated with a high risk
of breast cancer, other than high genetic risk, are associated with increa
sed exposure to oestrogens. Thus, therapeutic manoeuvres targeted at oestro
gen deprivation which have shown value in established breast cancers are at
tractive candidates for breast cancer prevention strategies. It is possible
that such agents may reduce the incidence of ER-negative as well as ER-pos
itive rumours. The potential use of these different drugs is restricted by
menopausal status, e.g. aromatase inhibitors only after the menopause, and
Gonadotropin-releasing hormone (GnRH) agonists prior to the menopause. Ther
e is a complex interplay between the anticipated benefit which may be deriv
ed from a respective agent and the side-effects associated with it. This ar
ticle seeks to integrate the information From several sources and concludes
that the prophylactic strategies should differ according to different risk
profiles. (C) 2000 Elsevier Science Ltd. All rights reserved.